Previously Treated CLL

CE

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL: Key Information for Nurses, NPs, and PAs

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Released: November 05, 2024

Expiration: July 30, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Currently, how confident are you in your ability to select and sequence treatment regimens and long-term treatment plans for individual patients with CLL/SLL to optimize clinical benefit?

2.

Per national guidance for treating patients with CLL, assessment of which of the following should be considered at baseline prior to initiation of a covalent BTK inhibitor?

3.

A 75-year-old man was diagnosed with CLL in 2008 (13q deletion, no TP53 abnormality, unmutated IGHV). He was treated with bendamustine plus rituximab in 2009; a complete response maintained until 2016. He then started ibrutinib in 2017 (13q and 11q deletions, no TP53 abnormality); arthralgias/myalgias led to switch to acalabrutinib. In 2021, progressive lymphocytosis and new adenopathy was noted along with a BTK C481S mutation. He started venetoclax plus rituximab; he completed 2-year treatment and achieved a complete response. After 2 years, new lymphocytosis, mild anemia, and palpable lymph nodes were noted; he began venetoclax monotherapy.

In your current practice, what would you consider to be the optimal therapy for this patient?